|
|
Article: Geron Corporation Announces Study Results Demonstrating the Utility of Telomerase Promoter-based therapies for cancer.
- Article from:
- Business Wire
- Article date:
- April 5, 2001
CopyrightCOPYRIGHT 2001 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors and Health/Medical Writers
MENLO PARK, Calif.--(BW HealthWire)--April 5, 2001
Geron Corporation (Nasdaq:GERN) announced today the publication of a study that demonstrates the utility of the human telomerase promoter to drive the preferential expression of therapeutic genes in cancer cells. The research, described in the April 4 issue of Gene Therapy, shows that the cloned promoter of the human telomerase reverse transcriptase (hTERT) gene can drive the selective expression of therapeutic genes in cancer cells in vitro and in vivo, while remaining inactive in normal somatic cells and tissues.
The research takes advantage of the ...